These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 38351946)

  • 1. Chronic cough: is the end nigh?
    Hirons B; Turner R; Cho PSP; Birring SS
    Breathe (Sheff); 2023 Dec; 19(4):230165. PubMed ID: 38351946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial.
    Smith JA; Kitt MM; Morice AH; Birring SS; McGarvey LP; Sher MR; Li YP; Wu WC; Xu ZJ; Muccino DR; Ford AP;
    Lancet Respir Med; 2020 Aug; 8(8):775-785. PubMed ID: 32109425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of gefapixant, a P2X
    McGarvey LP; Birring SS; Morice AH; Dicpinigaitis PV; Pavord ID; Schelfhout J; Nguyen AM; Li Q; Tzontcheva A; Iskold B; Green SA; Rosa C; Muccino DR; Smith JA;
    Lancet; 2022 Mar; 399(10328):909-923. PubMed ID: 35248186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Gefapixant, a P2X
    Ishiura Y; Nomura S; Ishii Y; Imai K; Sawai Y; Tamaki T; Shimizu T; Miyashita N; Ito T
    Int Med Case Rep J; 2023; 16():497-501. PubMed ID: 37692174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on the clinical development of gefapixant, a P2X3 receptor antagonist for the treatment of refractory chronic cough.
    Muccino D; Green S
    Pulm Pharmacol Ther; 2019 Jun; 56():75-78. PubMed ID: 30880151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of P2X3 receptor antagonist for the treatment of refractory or unexplained chronic cough: A systematic review and meta-analysis of 11 randomized controlled trials.
    Ramadan A; El-Samahy M; Elrosasy A; Al-Tawil M; Abdelaziz A; Soliman MA; Abouzid M
    Pulm Pharmacol Ther; 2023 Dec; 83():102252. PubMed ID: 37678663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of gefapixant, a P2X3 antagonist, on cough reflex sensitivity: a randomised placebo-controlled study.
    Morice AH; Kitt MM; Ford AP; Tershakovec AM; Wu WC; Brindle K; Thompson R; Thackray-Nocera S; Wright C
    Eur Respir J; 2019 Jul; 54(1):. PubMed ID: 31023843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An update and systematic review on drug therapies for the treatment of refractory chronic cough.
    Ryan NM; Vertigan AE; Birring SS
    Expert Opin Pharmacother; 2018 May; 19(7):687-711. PubMed ID: 29658795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, Pharmacodynamics, and Pharmacokinetics of P2X3 Receptor Antagonist Eliapixant (BAY 1817080) in Healthy Subjects: Double-Blind Randomized Study.
    Friedrich C; Francke K; Gashaw I; Scheerans C; Klein S; Fels L; Smith JA; Hummel T; Morice A
    Clin Pharmacokinet; 2022 Aug; 61(8):1143-1156. PubMed ID: 35624408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Efficacy and Safety of Gefapixant in a Phase 3b Trial of Patients with Recent-Onset Chronic Cough.
    McGarvey L; Sher M; Shvarts YG; Lu S; Wu WC; Xu P; Schelfhout J; La Rosa C; Nguyen AM; Reyfman PA; Afzal AS
    Lung; 2023 Apr; 201(2):111-118. PubMed ID: 36879087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Renal Impairment on the Pharmacokinetics of Gefapixant, a P2X3 Receptor Antagonist.
    Nussbaum JC; Hussain A; Min KC; Marbury TC; Lasseter K; Stoch SA; Iwamoto M
    J Clin Pharmacol; 2022 Nov; 62(11):1435-1444. PubMed ID: 35656754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough.
    Muccino DR; Morice AH; Birring SS; Dicpinigaitis PV; Pavord ID; Assaid C; Kleijn HJ; Hussain A; La Rosa C; McGarvey L; Smith JA
    ERJ Open Res; 2020 Oct; 6(4):. PubMed ID: 33263037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 3, randomized, double-blind, clinical study to evaluate the long-term safety and efficacy of gefapixant in Japanese adult participants with refractory or unexplained chronic cough.
    Niimi A; Sagara H; Kikuchi M; Arano I; Sato A; Shirakawa M; La Rosa C; Muccino D
    Allergol Int; 2022 Oct; 71(4):498-504. PubMed ID: 35752582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacotherapeutic Options for Chronic Refractory Cough.
    Song WJ; Chung KF
    Expert Opin Pharmacother; 2020 Aug; 21(11):1345-1358. PubMed ID: 32301356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ATP, an attractive target for the treatment of refractory chronic cough.
    Zhang M; Sykes DL; Sadofsky LR; Morice AH
    Purinergic Signal; 2022 Sep; 18(3):289-305. PubMed ID: 35727480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with the P2X3-Receptor Antagonist Gefapixant for Acute Cough in Induced Viral Upper Respiratory Tract Infection: A Phase 2a, Randomized, Placebo-Controlled Trial.
    Smith JA; Kitt MM; Bell A; Noulin N; Tzontcheva A; Seng MM; Lu S
    Pulm Ther; 2022 Sep; 8(3):297-310. PubMed ID: 35969360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Speech and language therapy for management of chronic cough.
    Slinger C; Mehdi SB; Milan SJ; Dodd S; Matthews J; Vyas A; Marsden PA
    Cochrane Database Syst Rev; 2019 Jul; 7(7):CD013067. PubMed ID: 31335963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of Patients With Refractory or Unexplained Chronic Cough Participating in a Phase 2 Clinical Trial of the P2X3-Receptor Antagonist Gefapixant.
    Morice AH; Birring SS; Smith JA; McGarvey LP; Schelfhout J; Martin Nguyen A; Xu ZJ; Wu WC; Muccino DR; Sher MR
    Lung; 2021 Apr; 199(2):121-129. PubMed ID: 33825965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Persistent Cough in Subjects with Idiopathic Pulmonary Fibrosis (IPF) with Gefapixant, a P2X3 Antagonist, in a Randomized, Placebo-Controlled Clinical Trial.
    Martinez FJ; Afzal AS; Smith JA; Ford AP; Li JJ; Li Y; Kitt MM;
    Pulm Ther; 2021 Dec; 7(2):471-486. PubMed ID: 34152585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms and Rationale for Targeted Therapies in Refractory and Unexplained Chronic Cough.
    Mazzone SB; McGarvey L
    Clin Pharmacol Ther; 2021 Mar; 109(3):619-636. PubMed ID: 32748976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.